GLP-1 Weight Loss Drugs Linked to Lower Risk of Age-Related Macular Degeneration
Non-diabetic adults over 50 who took GLP-1 drugs like semaglutide had a 39% lower rate of age-related macular degeneration compared to those on other weight loss medications.
Quick Facts
What This Study Found
In a propensity-matched retrospective study of 20,959 patients per group, GLP-1 receptor agonists were associated with a significantly lower hazard of nonexudative AMD (HR 0.47, 95% CI 0.28–0.78) and any AMD (HR 0.61, 95% CI 0.43–0.85) compared to other weight loss pharmacotherapies.
The difference for exudative (wet) AMD alone was not statistically significant (HR 0.63, 95% CI 0.30–1.32). Importantly, BMI and hemoglobin A1c trajectories were similar between the two groups over follow-up, suggesting the protective association is not simply driven by greater weight loss or metabolic improvement.
Key Numbers
How They Did This
This was a retrospective cohort study using de-identified data from the TriNetX Research Network (June 2021–October 2025). Researchers identified non-diabetic adults aged 50+ prescribed either GLP-1 receptor agonists or other weight loss drugs, requiring at least two prescriptions six months apart. After 1:1 propensity score matching on demographics, AMD risk factors, and access to eye care, 20,959 patients remained in each cohort. Outcomes were analyzed using Cox proportional hazards models.
Why This Research Matters
Age-related macular degeneration is the leading cause of irreversible vision loss in older adults, and treatment options for the dry form are extremely limited. If GLP-1 drugs genuinely reduce AMD risk through mechanisms beyond weight loss — possibly through anti-inflammatory or neuroprotective effects — it could represent an unexpected bonus for the millions already taking these medications and a new avenue for AMD prevention research.
The Bigger Picture
GLP-1 receptor agonists continue to show surprising benefits beyond weight loss and diabetes — from cardiovascular protection to kidney disease to now potentially eye health. This study adds to the growing picture of GLP-1 drugs as broadly protective, though the mechanisms in the retina remain unclear. Researchers suspect anti-inflammatory properties may be at play, since chronic inflammation is a key driver of AMD.
What This Study Doesn't Tell Us
This is a retrospective observational study, so it cannot prove causation — only association. The TriNetX database relies on diagnostic codes, which may miss early or undiagnosed AMD. The study excluded diabetic patients, so findings may not apply to those with diabetes. Follow-up duration was limited, and exudative AMD results were not statistically significant, possibly due to its lower incidence. There may be unmeasured confounders despite propensity matching.
Questions This Raises
- ?What biological mechanism might explain GLP-1 drugs' protective effect on the retina independent of weight loss?
- ?Would these findings hold up in a prospective randomized trial specifically designed to measure eye outcomes?
- ?Does the duration of GLP-1 use affect the degree of AMD risk reduction?
Trust & Context
- Key Stat:
- 53% lower risk of dry AMD GLP-1 users had roughly half the rate of nonexudative AMD compared to those on other weight loss drugs (HR 0.47)
- Evidence Grade:
- This is a large retrospective cohort study with propensity score matching, which provides moderate evidence. While the sample size is strong and matching was thorough, it cannot establish causation, and unmeasured confounders may exist.
- Study Age:
- Published in 2025 with data through October 2025, this is a very recent study reflecting the latest real-world evidence on GLP-1 drugs and eye health.
- Original Title:
- Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.
- Published In:
- Ophthalmology. Retina (2025)
- Authors:
- Myers, Walter K, Heath, Garrett, Rohrer, Bärbel
- Database ID:
- RPEP-12693
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs prevent age-related macular degeneration?
This study found an association between GLP-1 drug use and lower AMD rates, but it cannot prove the drugs prevent AMD. The finding needs confirmation in prospective clinical trials before any preventive claims can be made.
Why were only non-diabetic patients included in this study?
Diabetes itself is a major risk factor for eye disease, so including diabetic patients would make it harder to isolate the effect of GLP-1 drugs on AMD specifically. By excluding diabetics, the researchers could better assess whether GLP-1 drugs have eye-protective effects independent of diabetes management.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12693APA
Myers, Walter K; Heath, Garrett; Rohrer, Bärbel. (2025). Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.. Ophthalmology. Retina. https://doi.org/10.1016/j.oret.2025.12.016
MLA
Myers, Walter K, et al. "Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies.." Ophthalmology. Retina, 2025. https://doi.org/10.1016/j.oret.2025.12.016
RethinkPeptides
RethinkPeptides Research Database. "Rate of Age-Related Macular Degeneration in Patients Prescri..." RPEP-12693. Retrieved from https://rethinkpeptides.com/research/myers-2025-rate-of-agerelated-macular
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.